246 related articles for article (PubMed ID: 25596326)
1. Multivalent display of pendant pro-apoptotic peptides increases cytotoxic activity.
Chu DS; Bocek MJ; Shi J; Ta A; Ngambenjawong C; Rostomily RC; Pun SH
J Control Release; 2015 May; 205():155-61. PubMed ID: 25596326
[TBL] [Abstract][Full Text] [Related]
2. Two birds, one stone: dual targeting of the cancer cell surface and subcellular mitochondria by the galectin-3-binding peptide G3-C12.
Sun W; Li L; Li LJ; Yang QQ; Zhang ZR; Huang Y
Acta Pharmacol Sin; 2017 Jun; 38(6):806-822. PubMed ID: 28065935
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and evaluation of multivalent M2pep peptides for targeting alternatively activated M2 macrophages.
Ngambenjawong C; Cieslewicz M; Schellinger JG; Pun SH
J Control Release; 2016 Feb; 224():103-111. PubMed ID: 26772876
[TBL] [Abstract][Full Text] [Related]
4. Enhanced intracellular and intranuclear drug delivery mediated by biomimetic peptide SVS-1 for anticancer therapy.
Xiang Y; Chen L; Zhou R; Huang Y
Int J Pharm; 2019 Oct; 570():118668. PubMed ID: 31494237
[TBL] [Abstract][Full Text] [Related]
5. Water-soluble polymers for targeted drug delivery to human squamous carcinoma of head and neck.
Nan A; Ghandehari H; Hebert C; Siavash H; Nikitakis N; Reynolds M; Sauk JJ
J Drug Target; 2005 Apr; 13(3):189-97. PubMed ID: 16036307
[TBL] [Abstract][Full Text] [Related]
6. Design of integrin α
Lv X; Zhang C; Shuaizhen Q; Yu R; Zheng Y
Biomed Pharmacother; 2020 Aug; 128():110236. PubMed ID: 32447209
[TBL] [Abstract][Full Text] [Related]
7. Selective killing of cancer cells by peptide-targeted delivery of an anti-microbial peptide.
Sioud M; Mobergslien A
Biochem Pharmacol; 2012 Nov; 84(9):1123-32. PubMed ID: 22922046
[TBL] [Abstract][Full Text] [Related]
8. Intracellular delivery of a proapoptotic peptide via conjugation to a RAFT synthesized endosomolytic polymer.
Duvall CL; Convertine AJ; Benoit DS; Hoffman AS; Stayton PS
Mol Pharm; 2010 Apr; 7(2):468-76. PubMed ID: 19968323
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and in vitro anti-tumor activity of novel HPMA copolymer-drug conjugates with potential cell surface targeting property for carcinoma cells.
Xiang Q; Yang Y; Zhou Z; Zhou D; Jin Y; Zhang Z; Huang Y
Eur J Pharm Biopharm; 2012 Feb; 80(2):379-86. PubMed ID: 22101181
[TBL] [Abstract][Full Text] [Related]
10. Synthesis of a catalytic nanomaterial from polypyrrole and a pro-apoptotic peptide to target mitochondria for multimodal cancer therapy.
Wang C; Tian X; Li X
Org Biomol Chem; 2024 Jun; 22(24):4958-4967. PubMed ID: 38819437
[TBL] [Abstract][Full Text] [Related]
11. An in-tether chiral center modulates the proapoptotic activity of the KLA peptide.
Li J; Hu K; Chen H; Wu Y; Chen L; Yin F; Tian Y; Li Z
Chem Commun (Camb); 2017 Sep; 53(75):10452-10455. PubMed ID: 28884757
[TBL] [Abstract][Full Text] [Related]
12. Synergistic effect of the pro-apoptosis peptide kla-TAT and the cationic anticancer peptide HPRP-A1.
Hu C; Chen X; Huang Y; Chen Y
Apoptosis; 2018 Feb; 23(2):132-142. PubMed ID: 29397453
[TBL] [Abstract][Full Text] [Related]
13. Coadministration of kla peptide with HPRP-A1 to enhance anticancer activity.
Hao W; Hu C; Huang Y; Chen Y
PLoS One; 2019; 14(11):e0223738. PubMed ID: 31703065
[TBL] [Abstract][Full Text] [Related]
14. Synergistic enhancement of anticancer therapeutic efficacy of HPMA copolymer doxorubicin conjugates via combination of ligand modification and stimuli-response srategies.
Li L; Zhou M; Huang Y
Int J Pharm; 2018 Jan; 536(1):450-458. PubMed ID: 29237570
[TBL] [Abstract][Full Text] [Related]
15. Optimization of Tet1 ligand density in HPMA-co-oligolysine copolymers for targeted neuronal gene delivery.
Chu DS; Schellinger JG; Bocek MJ; Johnson RN; Pun SH
Biomaterials; 2013 Dec; 34(37):9632-7. PubMed ID: 24041424
[TBL] [Abstract][Full Text] [Related]
16. iRGD-targeted delivery of a pro-apoptotic peptide activated by cathepsin B inhibits tumor growth and metastasis in mice.
Qifan W; Fen N; Ying X; Xinwei F; Jun D; Ge Z
Tumour Biol; 2016 Aug; 37(8):10643-52. PubMed ID: 26867766
[TBL] [Abstract][Full Text] [Related]
17. Bladder tumor-targeted delivery of pro-apoptotic peptide for cancer therapy.
Jung HK; Kim S; Park RW; Park JY; Kim IS; Lee B
J Control Release; 2016 Aug; 235():259-267. PubMed ID: 27282414
[TBL] [Abstract][Full Text] [Related]
18. Reducible HPMA-co-oligolysine copolymers for nucleic acid delivery.
Shi J; Johnson RN; Schellinger JG; Carlson PM; Pun SH
Int J Pharm; 2012 May; 427(1):113-22. PubMed ID: 21893178
[TBL] [Abstract][Full Text] [Related]
19. Co-administration of kla-TAT peptide and iRGD to enhance the permeability on A549 3D multiple sphere cells and accumulation on xenograft mice.
Hu C; Chen X; Huang Y; Chen Y
Chem Biol Drug Des; 2018 Aug; 92(2):1567-1575. PubMed ID: 29722179
[TBL] [Abstract][Full Text] [Related]
20. Enhanced anticancer efficacy of paclitaxel through multistage tumor-targeting liposomes modified with RGD and KLA peptides.
Sun J; Jiang L; Lin Y; Gerhard EM; Jiang X; Li L; Yang J; Gu Z
Int J Nanomedicine; 2017; 12():1517-1537. PubMed ID: 28280323
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
